Board summary
Key figures
27,096
Registered population
62.5% aged 18–64
14.2%
Aged 65+
ICB 14.9% · England 17.9%
46.4%
Ethnic minority (non-White)
35.2% Asian · England 9.6%
74.1%
In IMD quintile 1
ICB 40.7% · England 21.0%
~14,925
Core20 residents (est.)
Resident basis; registered basis ~22,073 · see page 3
3,461
Hypertension register
+0.98% in 3 yrs · England +5.60%
372
SMI register
10.3% of Bolton (LAD)'s
702
COPD register
Reviews -13.43% in 3 yrs
Forecast to 2030
3,620
Hypertension patients, 2030
+159 on today
63.7%
QRISK ≥20% on statins, 2030
+0.06pp over 3 yrs
3.2%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
COPD and heart failure reviews fell sharply.
Over 2023 to 2025, COPD reviews fell 13.4% to 67.0% (England +2.8%) and heart failure reviews fell 10.5% to 74.8% (England +8.7%).
Cervical screening at ages 25-49 lags England.
Coverage is 52.4%, trailing Bolton (LAD) (63.9%) and England (66.8%) by 14.5 pp after falling 8.1% over 2023 to 2025 (England -1.0%).
Mental health checks and breast screening rose.
Over 2023 to 2025, mental health register blood pressure checks rose +6.6 pp to 80.5% (England +4.4 pp); breast screening rose +9.3% to 67.7%.
Population, age and ethnicity
Younger age structure and 35.2% Asian ethnicity may shape local service demand
HWL NETWORK PCN serves 27,096 registered patients. Children aged 0-17 comprise 23.3% of the list, below Bolton (23.7%) by 0.4 pp but above the ICB (21.8%) and England (19.6%). Patients aged 65+ account for 14.2%, below Bolton (14.7%), the ICB (14.9%) and England (17.9%). In associated resident areas, Census data shows 35.2% Asian or Asian British residents, exceeding Bolton (20.1%), the ICB (13.6%) and England (9.6%), alongside 53.6% White residents. Age profiles reflect registered patients, whereas ethnicity measures Census usual residents in associated areas.
Age profile
65+: ICB 14.9%, England 17.9%
Ethnicity
Older people · falls rows are Bolton (LAD) local-authority (LA) data, not PCN
| Measure | Local | North West | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Bolton LA) | 1,923 | 2,071 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 85.0% | 82.9% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 51.3% | 56.6% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Bolton LA) | 958 | 1,021 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Bolton LA) | 19.0 | 18.2 | 14.8 | 2022‑24 |
Deprivation and Core20
Core20 deprivation reaches 74.1% PCN-wide but spans 60.5 pp between member practices
Core20 deprivation reaches 74.1% of registered patients across the PCN, exceeding Bolton (LAD) (47.8%), NHS Greater Manchester Integrated Care Board (40.7%), and England (21.0%). Average IMD decile is 2.8 (England 5.5). Across captured practices, Core20 shares span a 60.5 pp range. Burnside Surgery records 39.5%, whereas Octagon Medical Centre records 100.0%. Practice-level estimates sum to 22,073 registered patients compared with a PCN resident estimate of 14,925, indicating denominator differences that require reconciliation before targeting.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
372
SMI register
1.36% recorded prevalence
190
Learning disability register
0.70% recorded prevalence
15
Care homes, 281 beds
In the PCN catchment
9.8%
Provide unpaid care
Bolton (LAD), Census 2021
The PCN records 372 severe mental illness patients (1.4% prevalence, above Bolton's 1.1%, the ICB's 1.1% and England's 1.0%) and 190 learning disability patients (0.7%, above Bolton, the ICB and England at 0.6%). Catchment data lists 281 care home beds across 15 sites, though occupancy is unconfirmed.
Severe mental illness: physical health checks
SMI prevalence is 1.4% (England 1.0%). Recorded blood pressure checks reached 80.5% (England 83.4%) and BMI was 79.3% (England 82.1%). Checks trail national benchmarks, which may reflect recall gaps, unverified locally; audits would test this.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
3,461
Hypertension register
+0.98%
Register growth, 3 yrs
Bolton (LAD) +4.70% · England +5.60%
+1.54pp
BP control, under 80
≤140/90 · +0.24pp aged 80+
+159
More patients by 2030
Forecast 3,620 (12.93%)
Hypertension case-finding and control
Recorded hypertension prevalence is 12.7% (3,461 patients), below Bolton (14.8%), NHS Greater Manchester Integrated Care Board (14.4%) and England (15.2%), with register growth of +1.0% over 2023 to 2025 lagging England (+5.6%). This yields an unadjusted register gap of +537 to +666 patients, though this is not age-adjusted for a younger population (14.2% aged 65+ versus 17.9% in England). Among recorded patients, 89.7% had a recent blood pressure check (England 90.0%) and 69.2% are treated to target (England 70.3%). Lower recorded prevalence may reflect age structure or under-detection, unverified locally; case-finding audits would test this.
Lipids and statins
QRISK ≥ 20% lipid therapy is 63.6%, matching England (63.6%) but trailing NHS Greater Manchester Integrated Care Board (67.0%), with change of +0.1% over 2023 to 2025 lagging England (+6.2%). Primary diabetes statin therapy is 71.6% (England 73.2%). Trailing the ICB may indicate variation in statin initiation, unverified locally; structured reviews would test this.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 48,008 | £1.40 | £1.94 | £1.86 | £67,211 |
| Cardiovascular (all), 2025 | 66,485 | £2.90 | £3.15 | £3.33 | £192,806 |
For lipid-regulating drugs in 2026, the PCN prescribed 48,008 items at £1.40 per item, below Bolton (£1.81), NHS Greater Manchester Integrated Care Board (£1.94) and England (£1.86). Across 48,008 items, this is £22,084 less than at England's unit cost. This unit-cost indicator does not reflect efficiency, treatment appropriateness or formulary choices.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
−3.72%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
−6.11%
Asthma prevalence, PCN 3-yr % change
COPD prevalence is 2.6% (702 patients), but reviews fell 13.4% over 2023 to 2025 to 67.0% (England +2.8% to 76.4%). Asthma prevalence is 6.4% (1,619 patients), with reviews down 3.7% over 2023 to 2025 (England +4.4%) to 65.6%, leaving about 560 unreviewed. Concurrently, youth asthma prescribing reached 2,284 items per 1,000 (England 1,488) and second-hand smoke recording was 70.5% (England 78.8%). Heavy prescribing alongside falling reviews may reflect unreviewed symptom burden, unverified locally; record audits would test this.
Cancer register and children's immunisation
Cancer recorded prevalence is 2.9% (781 patients; England 3.8%). In Q1 2025/26, 12-month 6-in-1 coverage was 86.8% (England 91.0%), below the 95.0% target by 8.2 pp. By age 5, MMR1 reached 96.9% and MMR2 92.8% (a 4.1 pp difference). Early infant vaccination lags before catching up, which could reflect early access friction, unverified locally; outreach audits would test this.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
55.6%
Greater Manchester ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~2,270
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Greater Manchester ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Lung | 40.4% | 33.8% | 15% | 2,193 |
| Prostate | 61.7% | 53.2% | 14% | 1,788 |
| Breast | 82.5% | 85.4% | 19% | 1,758 |
| Bowel | 46.3% | 47.0% | 19% | 1,427 |
| Skin cancer | 84.5% | 87.8% | 27% | 580 |
In 2022, 55.6% of staged cancers across NHS Greater Manchester ICB were diagnosed at stage 1 or 2 (England 55.3%), showing a distance of -19.4 pp to the 75.0% national ambition by 2028, representing about 2,270 extra early-stage cases. Known-stage share was 70.8% (England 67.0%). Wider early detection links with primary care screening: PCN cervical screening coverage for women aged 25-49 is 52.4% (England 66.8%, Bolton 63.9%), after falling 8.1% over 2023 to 2025 (England -1.0%). Lower cervical screening uptake across the network could delay early detection, making proactive recall an operational priority.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In provisional July 2026 data, Bolton NHS Foundation Trust met the 28-day faster diagnosis standard at 80.5% (ICB 79.5%, England 79.3%) and the 31-day standard at 96.5% (ICB 96.5%, England 92.5%). On 62-day treatment, Bolton NHS Foundation Trust reached 69.7%, a distance of -15.3 pp to the 85.0% standard (Wrightington, Wigan and Leigh Teaching Hospitals NHS Foundation Trust 76.8%, Northern Care Alliance NHS Foundation Trust 78.6%, ICB 75.7%, England 71.2%). For diagnostics, 25.3% of cystoscopy patients waited 6+ weeks at Bolton NHS Foundation Trust (England 24.4%), while MRI waits were 2.0%.
| Pathways within standard (%) | Bolton | Northern Care Alliance | Wrightington, Wigan and Leigh | Greater Manchester ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 80.48 | 75.20 | 82.80 | 79.53 | 79.32 |
| 31-day treatment (96%) | 96.50 | 94.54 | 89.04 | 96.49 | 92.50 |
| 62-day referral to treatment (85%) | 69.66 | 78.65 | 76.78 | 75.73 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Bolton | Northern Care Alliance | Wrightington, Wigan and Leigh | England |
|---|---|---|---|---|
| MRI | 2.05 | 5.09 | 0.49 | 21.40 |
| CT | 19.40 | 4.10 | 7.78 | 9.92 |
| Echocardiography | 3.48 | 31.48 | 24.37 | 28.48 |
| Colonoscopy | 1.33 | 40.04 | 6.10 | 30.83 |
| Gastroscopy | 2.06 | 36.48 | 12.54 | 29.02 |
| All 15 DM01 tests | 15.78 | 15.71 | 14.36 | 23.14 |
| Community services activity | Bolton residents | Greater Manchester ICB |
|---|---|---|
| Care contacts | 49,315 | 573,310 |
| Referrals | 4,075 | 94,470 |
| Patients with a contact | 17,765 | 183,535 |
Community services (residents of Bolton), Jun 2026 (provisional). In provisional June 2026 data, 51.6% of community service contacts for Bolton borough residents were with adults aged 65 and over (25,460 of 49,315 contacts). This caseload reflects borough-level activity rather than PCN provision, indicating substantial older-age community service demand.
Practice variation and patient experience
Phone access spans 22.9 pp across practices while vaccination achievement spans 56.9 pp
In 2025/26, clinical QOF achievement reached 100.0% at Dr Rizwan And Dr Awan, yet vaccination and immunisation achievement spanned 56.9 pp, from 15.6% at Dr Rizwan And Dr Awan to 72.6% at Charlotte Street Surgery. Personalised care adjustment rates spanned from 4.9% at Burnside Surgery to 15.2% at Octagon Medical Centre (England 10.0%).
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Halliwell 2 | 105 | 93.8 | 90.3% | 91.0% | 87.1% |
| Burnside Surgery | 124 | 39.5 | 74.7% | 68.0% | 86.5% |
| Dr Rizwan And Dr | 93 | 78.3 | 89.2% | 82.6% | 84.8% |
| Octagon | 91 | 100.0 | 73.9% | 74.7% | 81.4% |
| Halliwell 3 | 98 | 90.9 | 87.3% | 78.4% | 81.0% |
| Charlotte Street | 77 | 79.1 | 67.4% | 85.6% | 71.8% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Eighteen of 25 compared measures trailed England over three years, led by falling reviews
Over 2023 to 2025, 18 of 25 compared measures trailed England. Annual reviews fell: heart failure reviews fell 10.5% (England +8.7%), COPD reviews fell 13.4% (England +2.8%), and asthma reviews fell 3.7% (England +4.4%), while cervical screening fell 8.1% (England -1.0%). In contrast, severe mental illness checks improved ahead of England: blood pressure checks rose +6.6 pp (England +4.4 pp) with current coverage at 80.5%, and alcohol recording rose +7.0 pp (England +5.4 pp) with current coverage at 78.4%. Over 2023 to 2024, breast screening rose +9.3% (England +8.4%).
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Heart failure reviews
COPD reviews
Asthma reviews
Depression register
Cervical screening
BP check (SMI)
Alcohol record (psychosis)
Breast screening (53-70)
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Bolton (LAD) | Asset | PCN | Bolton (LAD) |
|---|---|---|---|---|---|
| Care homes (catchment) | 15 (281 beds) | n/a | Schools (catchment) | 48 | n/a |
| Children's centres | 3 | 18 | Places of worship | 37 | 144 |
| Libraries | 1 | 7 | Primary schools (LA maintained) | 12 | 61 |
| Primary academies | 4 | 32 | Special schools | n/a | 3 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Structured asthma and COPD review recall
Asthma reviews fell 3.7% over 2023 to 2025 (England +4.4%) to 65.6% of 1,619 patients (about 560 unreviewed); COPD reviews fell 13.4% to 67.0% of 702 (England 76.4%). For discussion: run single-template asthma and COPD recall with after-school slots and inhaler checks. Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 2
Targeted Core20 hypertension case-finding
Recorded hypertension is 12.7% (3,461 patients) versus 14.8% in Bolton and 15.2% in England (+1.0% three-year growth versus England +5.6%), an unadjusted gap of +537 to +666. For discussion: audit uncoded raised blood pressure readings and run opportunistic checks in high-Core20 practices. Low cost, quick to run.
Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.
Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).
Option 3
Cervical screening recall and access recovery
Cervical screening at ages 25-49 is 52.4%, below Bolton (63.9%) by 11.5 pp, the ICB (65.9%) by 13.5 pp, and England (66.8%) by 14.5 pp after falling 8.1% over 2023 to 2025 (England -1.0%). For discussion: follow up non-responders with adapted reminders, telephone outreach, and evening or weekend screening slots. Moderate effort to run.
Evidence base: uptake is the delivery measure of the national cancer screening programme; distance to the acceptable and achievable standards is the outreach target.
Policy anchor: Shift 3: sickness to prevention; Eliminate cervical cancer by 2040.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Culturally tailored access review (p2) | Asian / Asian British | Neighbourhood health framework · Core20PLUS5 approach | PCN |
| Core deprivation list reconciliation (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| SMI physical check recall audit (p4) | SMI register with a BP check in the last 12 months | MHIS · From Harm to Hope | PCN |
| Hypertension case finding audit (p5) | Hypertension: QOF prevalence | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Infant immunisation recall outreach (p6) | 6-in-1 coverage at 12 months | 10YHP sickness to prevention · 95% target | PCN |
| Cervical screening recall recovery (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
| Telephony and patient access review (p9) | GPPS easy to contact the practice by phone | 10YHP, hospital to community | Practice |
| Option 1 · Structured asthma and COPD review recall (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) · COPD register | Core20PLUS5 respiratory | PCN |
| Option 2 · Targeted Core20 hypertension case-finding (p12) | Hypertension register · Hypertension: QOF prevalence · Aged 65+ | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Option 3 · Cervical screening recall and access recovery (p12) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) · Core20 cohort (IMD quintile 1) · Asian / Asian British | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | Local authority | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
